This review highlights emerging therapeutic strategies targeting the nitric oxide pathway for the treatment of pulmonary arterial hypertension.
Clinical trials of inhaled nitrite to treat pulmonary arterial hypertension (PAH) are ongoing. The pathogenesis of PAH involves smooth muscle hypertrophy as a result of endothelial dysfunction and/or chronic vasoconstriction. Nitric oxide (NO) is a potent vasodilator and a primary therapeutic pathway for PAH. This review will address some of the emerging PAH treatment strategies utilizing the NO pathway.
No takes yet. Share an insight, caveat, or question.
Marc A. Simon (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: